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Introduction 38
There is a drastic need for innovative therapeutic solutions that selectively target multi-drug 39 resistant Gram-negative infections. This can be attributed to resistance to nearly all 40 conventional antibiotics used clinically, and a lack of effective antibiotics in reserve. negative bacteria, particularly: Pseudomonas aeruginosa, Escherichia coli, Klebsiella 42 pneumoniae and Acinetobacter baumannii, are an ever-increasing threat to health and particularly that of hospitalized patients who commonly are immunocompromised, have co-44 morbidities and are less able to fight infection [1] . Recently, emphasis has been placed on the 45 rapid detection of specific, causative antimicrobial resistant strains. This has catalysed the 46 drive to develop pathogen-specific, narrow spectrum antimicrobials. This change in focus 47 from broad-spectrum microbial annihilation to more targeted therapy, acknowledges the 48 major contribution empirical prescribing has on increasing drug resistance, and its impact on 49 beneficial human microbiota [2] . 50 51 Nosocomial infections are a major contributor to healthcare associated infections and 52 antimicrobial resistance. Approximately 20-40% are attributed to transfer of commensal 53 microorganisms from the skin of healthcare workers to patients or even the patients' own 54 commensal flora [3] . Healthcare associated infections affect approximately 4.1 million 55 patients annually within the European Union. They are a major contributor to morbidity 56 causing 37, 000 deaths annually and a further 100,000 deaths in those with co-morbidities 57 [4] . In terms of antimicrobial resistant infections, recent UK government reports estimate that 58 these contribute to around 25,000 deaths annually in Europe alone [5] . 59 60 Gram-negative bacteria are a particular problem due to multiple inherent resistance 61 mechanisms, most notably the presence of a lipopolysaccharide (LPS) outer membrane and 62 efflux pumps [6] . As a result of improper and overuse of antimicrobials, the resistance rates 63 to current therapeutic agents have increased to serious levels. This dilemma has attracted the 64 attention of scientists, the general public, health authorities and politicians. It is now 65 recognized as a considerable global health problem [3] . As mentioned, the significant lack of 66 newly licensed antimicrobial pharmaceuticals translating from the laboratory to patients is concerning. In the past 25 years, only two new cephalosporin-beta-lactamase inhibitor 68 combinations-ceftolozane/tazobactam in 2014 and ceftazidime/avibactam in 2015 have been 69 approved to treat systemic bacterial infections caused by multi-drug resistant Gram-negative 70 bacteria [7] . There are a multitude of reasons for the decline in antimicrobial drug 71 development, most notably the high financial commitment and time required for developing 72 and registering a new drug. On average it costs approximately $800 million to introduce a 73 new drug to market with development times normally in excess of 10 years. Parallel to this, 74 the pharmaceutical industry has focused over the past 30 years on the more financially 75 rewarding novel therapies for chronic diseases such as diabetes and cardiovascular disorders. 76
These products are likely to be required as lifetime treatments in contrast to antibiotics that 77 are most commonly short-term acute treatments (typically 5-14 days) [8] . Other contributing 78 factors include clinical trial requirements, particularly the challenge of proving novel 79 therapies produce greater clinical outcomes compared to existing products, and that they are 80 sufficiently safe for use. Pharmaceutical companies also express reservations about future 81 resistance development that may reduce drug longevity [9] [10] . In order to increase the 82 approval and registration of new antimicrobials, the US Food and Drug Administration have 83 indicated that it may be ready to alter its strict clinical-trial requirements and reassess the 84 antimicrobial approval regulations in order to increase the potential availability of novel 85 treatments [11] . The primary barriers to overcome, as will be discussed further in this review, 86 include the specific targeting of Gram-negative bacteria in order to produce selective 87 antibiotics that are suitable candidates for clinical trials and transition from the lab bench to 88 the clinic. 89
90
The Gram-negative outer membrane as a barrier to therapy 91
I. Bacterial cell wall structure 92
Understanding the mechanisms that govern Gram-negative bacterial resistance requires a 93 fundamental appreciation of their cell morphology. The unique structure of the outer 94 membrane of Gram-negative bacteria plays an important role, providing an additional layer 95 of mechanical protection, without affecting the selectivity or exchange of material needed for 96 bacterial survival [12] . The Gram-negative cell wall is composed of an outer LPS membrane 97 and an inner cytoplasmic membrane. A thin layer of peptidoglycan and lipoproteins exist 98 within the periplasmic space. The inner cell membrane is composed of a phospholipid 99 bilayer, whilst the outer membrane consists of phospholipids on its interior leaflet and of LPS 100 on its outer leaflet [13] . Porins and specialized transporters are also present within the outer 101 membrane channels and mediate the influx of a variety of compounds including nutrients and 102 minerals such as sugars, amino acids, phosphates and ions. Porins play an important role in 103 bacterial metabolism and growth, and are therefore a valuable target for antimicrobial drug 104 development [14] . Gram-negative bacteria continuously alter the expression and function of 105 outer membrane porins hence this may affect the sensitivity of antimicrobial agents. Loss of 106 or changes in porin amino acids could influence the ability or rate of entry of antibiotics and 107 contribute to resistance. In contrast to Gram-negative bacteria, Gram-positive bacteria lack an 108 outer membrane and are composed of a single lipid membrane surrounded by numerous 109 interconnecting layers of peptidoglycan and lipoteichoic acid ( 
II. Antimicrobial resistance mechanisms of Gram-negative bacterial cell wall 115
The outer membrane of Gram-negative bacteria acts as a selective barrier by adding a 116 hydrophobic lipid bilayer to the specific size-exclusion properties of porins. The outer 117 membrane has the ability to block the entry of numerous toxic compounds and prevent the 118 uptake of molecules with a molecular mass greater than 600 Daltons [16] . The influx of 119 metabolites such as sugars, phosphates and hydrophilic molecules is mainly directed by 120 porins. The continuous alteration in lipid or protein composition of the outer membrane leads 121 to drug-resistance. This involves the increasing of outer membrane hydrophobicity, changing 122 porin specificity or increasing the number and efficacy of efflux pumps [17] . 123
124
Reducing the negative charge of LPS within the bacterial outer membrane is one of the key 125 strategies employed by Gram-negative bacteria to negate the action of membrane active 126 cationic antimicrobials, such as chlorhexidine and cationic antimicrobial peptides. This is 127 achieved via the addition of positively charged residues such as aminoarabinose and 128 galactosamine sugars to LPS or by the removal of negative charged moieties. This 129 modification leads to increased bacterial survival as demonstrated by both Pseudomonas 130 aeruginosa and Francisella novicida after exposure to the cyclic cationic lipopeptide 131 polymyxin B [18] . Amines are also harnessed by Gram-negatives to increase LPS membrane 132 cationicity as demonstrated by Salmonella typhimurium which increases tolerance to 133 polymyxin B by conjugating phosphoethanolamine to one of the phosphate groups present 134 within outer membrane lipid A [19] . Bacteria are also able to remove anionic phosphate 135 groups to reduce the overall anionic surface charge of LPS, proven by the removal of the 4′-136 phosphate group from lipid A in Helicobacter pylori. This results in increased resistance to 137 membrane active cationic antimicrobial peptides [20] . Phospholipids present in the Gram-138 negative outer membrane are also susceptible to modification. Salmonella typhimurium has 139 the ability to increase the levels of outer membrane glycerophospholipids resulting in 140 increased membrane hydrophobicity and reducing the permeability of charged, water soluble 141 molecules [21] . identified in an Escherichia coli isolate present in a pig in China, encodes an enzyme that 213 directs the addition of phosphoethanolamine to lipid A decreasing the anionic charge of the 214 outer membrane. Whilst this addition has been elucidated previously, the fact that the process 215 is mediated via a plasmid is crucially significant, as it will allow resistance to readily spread 216 to other species. This discovery highlights the urgent need for investment to elucidate 217 antimicrobial resistance mechanisms and for tailored therapies to combat these. 218
219
Research into polymyxin-like molecules has been on-going, especially with regard to 220 producing less toxic derivatives (nephro-and neuro-toxic) and compromising the integrity of 221 the Gram-negative outer membrane barrier to increase the activity of existing antibiotics [35] . 222
Structurally similar cyclic antimicrobial peptides are also of interest as future synthetic 223 therapies as they possess increased serum stability relative to linear forms. They may also 224 provide a basis for designing cost-effective, low molecular mass, anti-LPS compounds [36] . 225
Cyclic peptide variants are synthesised by directly conjugating the two terminals of the 226 primary amino acid sequence to form an amide bond, or via another form of linkage such as 227 lactone or disulfide bonds. Generally, cyclic peptides are more effective than their linear 228 analogues because of the structural rigidity that enables cyclic peptides to bind selectively to 229 bacterial targets. They can also adapt an ordered amphipathic structure that allows them to 230 insert deeper within the bacterial membrane, with extended action in vivo due to their 231 increased stability to proteases [37] . Almost all known natural cyclic peptides display high 232 antibacterial activity. For example, polymyxin B, colistimethate and gramicidin S show high 233 bactericidal activity against Pseudomonas aeruginosa with minimum bactericidal 234 concentrations of 0.125, 4 and 8 μg/ml respectively [38] . Despite their significant bacterial 235 activity in vitro, many cyclic peptides are highly haemolytic and currently lack the bacterial 236 selectivity required for clinical translation [39] . 237 238
II. Combinational antibiotic treatment for Gram-negative bacteria 239
Synergistic therapy, a combination of two or more antibiotics, is a commonly employed 240 strategy to resolve Gram-negative infections. In comparison to monotherapy, combination 241 therapy takes advantage of the additive effects of multiple antimicrobial mechanisms for each 242 drug therapy to lower the risk of resistance developing. Combination therapy has also been 243 demonstrated to lower mortality and improve clinical outcomes. It is recommended for 244 patients whose infection is suspected or confirmed to be multidrug-resistant Gram-negative 245 bacteria [40] . Synergy between two or more antimicrobial agents means that the combined 246 effect will be greater than their individual effects. 
III. The activity of silver against Gram-negative bacterial infection 261
Silver has been known to protect against infection for over 2,000 years and continues to be 262 used widely in many antimicrobial applications, especially within the biomaterial industry. 263
Morones-Ramez and colleagues demonstrated that silver ions (Ag + ) have a synergistic effect 264 with beta-lactam, aminoglycoside and quinolone antibiotics against a variety of Gram-265 negative bacteria. Silver has been shown to increase the production of reactive oxygen 266 species, including hydroxyl radicals (OH•), increasing the permeability of the outer 267 membrane to commonly employed antibiotics [44] . Silver also acts intracellularly to 268 inactivate bacterial protein synthesis and enzymes responsible for a range of biochemical 269 processes, including deoxyribonuclease and ribonuclease. Silver has also been implicated in The increasing resistance of Gram-negative bacteria to a multitude of currently available 594 antibiotics requires urgent action. Research regarding novel alternative therapies has focused 595 on a variety of strategies, many of which have failed to progress successfully to clinical 596 translation and utilisation for patient benefit. The majority of approaches have focused on 597 extending the spectrum of activity of current Gram-positive targeting molecules to Gram-598 negatives. Whilst this warrants attention and should not be dismissed, a narrow spectrum, 599 species targeted approach is likely to be more beneficial with greater consideration of a 600 healthy commensal microbiota. This approach requires increased ability to rapidly diagnose 601 and detect specific causative microorganisms implicated infection so that optimal targeted 602 therapy can be provided. into clinical trials highlighting the importance of pharmaceutical formulation in advancing 619 molecular targets. Improving antibiotic delivery using liposomes or nanotubes is another 620 encouraging approach to extend therapeutic activity of conventional antibiotics against Gram-621 negatives. There is real hope for progress within this area especially as liposomal approaches 622 have successfully resulted in licensed formulations for a variety of drugs including the 623 antifungal amphotericin B. Engineered lysins have proven to be a truly alternative approach 624 resulting in a new class of antimicrobials. However, this approach still requires further 625 investigation particularly with regard to patient safety and their likelihood to develop 626 resistance. 627 628
Future Perspectives 629
• Combination therapy is recommended for patients at high risk of being infected with 694 multidrug-resistant Gram-negative bacteria, demonstrating lower mortality rates and 695 improved clinical outcomes. 696
III. The activity of silver against Gram-negative bacterial infection 697
• Silver increases the permeability of Gram-negative bacterial membranes and can 698 potentiate the activity of a broad range of antibiotics against these microorganisms. 699
• Silver nanoparticles have attracted interest due to their potential applications within 700 wound dressings, medical device coatings, and drug delivery. • Encapsulating narrow spectrum Gram-positive selective antibiotics within fusogenic 722 liposomes has been shown to broaden their spectrum of activity to cover Gram-negative 723 infections by enabling transversion across the outer membrane. 724
II. Carbon and peptide nanotubes 725
• Single-walled carbon nanotubes may be useful in molecules as future antimicrobials due 726 to their inherent antimicrobial properties and ability to deliver existing and future 727 antibiotic molecules via nanoparticle-based drug delivery. 728
• Cyclic D, L-alpha peptides are able to selectively target bacterial cell membranes, 729
including the outer membrane of Gram-negatives. They are able to self-assemble, 730 forming peptide nanotubes with the potential to act as biofunctional nanomaterials and 731 improve intracellular delivery of antibiotics. 732
III. Targeting Gram-negative pathogens with an engineered phage lytic enzyme 733
• Phage lytic enzymes can be engineered to cross the outer envelope of targeted Gram-734 negative bacteria. This is achieved by production of a "hybrid lysin" and "artilysin" that 735 have the ability to kill pathogenic Escherichia coli strains and Pseudomonas aeruginosa. 736 737
